uPA/uPAR and SERPINE1 in head and neck cancer : Role in tumor resistance, metastasis, prognosis and therapy
Pavón, Miguel Angel (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Arroyo-Solera, Irene (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Céspedes, María Virtudes (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Casanova Rigat, Isolda (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
León i Vintró, Xavier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Mangues, Ramon 1957- (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Universitat Autònoma de Barcelona

Date:	2016
Abstract:	There is strong evidence supporting the role of the plasminogen activator system in head and neck squamous cell carcinoma (HNSCC), particularly of its uPA (urokinase plasminogen activator)/uPAR (urokinase plasminogen activator receptor) and SERPINE1 components. Overexpression of uPA/uPAR and SERPINE1 enhances tumor cell migration and invasion and plays a key role in metastasis development, conferring poor prognosis. The apparent paradox of uPA/uPAR and its inhibitor SERPINE1 producing similar effects is solved by the identification of SERPINE1 activated signaling pathways independent of uPA inhibition. Both uPA/uPAR and SERPINE1 are directly linked to the induction of epithelial-to-mesenchymal transition, the acquisition of stem cell properties and resistance to antitumor agents. The aim of this review is to provide insight on the deregulation of these proteins in all these processes. We also summarize their potential value as prognostic biomarkers or potential drug targets in HNSCC patients. Concomitant overexpression of uPA/uPAR and SERPINE1 is associated with a higher risk of metastasis and could be used to identify patients that would benefit from an adjuvant treatment. In the future, the specific inhibitors of uPA/uPAR and SERPINE1, which are still under development, could be used to design new therapeutic strategies in HNSCCs.
Grants:	Ministerio de Economía y Competitividad PI14/01918 Ministerio de Economía y Competitividad PI15/00378 Ministerio de Economía y Competitividad PI15/00500 Ministerio de Economía y Competitividad PIE15/00028
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Subject:	Head and neck cancer ; Prognosis ; SERPINE1 ; Upa ; Upar
Published in:	Oncotarget, Vol. 7 Núm. 35 (2016) , p. 57351-57366, ISSN 1949-2553

DOI: 10.18632/oncotarget.10344
PMID: 27385000

16 p, 2.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles
Articles > Reviews